The Cigna Group (NYSE:CI) Given New $382.00 Price Target at Barclays

The Cigna Group (NYSE:CI - Get Free Report) had its target price boosted by stock analysts at Barclays from $339.00 to $382.00 in a report released on Monday,Benzinga reports. The brokerage currently has an "overweight" rating on the health services provider's stock. Barclays's target price would suggest a potential upside of 14.21% from the stock's previous close.

A number of other analysts have also commented on CI. Morgan Stanley decreased their target price on The Cigna Group from $403.00 to $379.00 and set an "overweight" rating for the company in a research report on Friday, January 31st. Cantor Fitzgerald upped their target price on shares of The Cigna Group from $350.00 to $365.00 and gave the stock an "overweight" rating in a research note on Thursday, March 20th. Mizuho raised their price objective on shares of The Cigna Group from $360.00 to $384.00 and gave the stock an "outperform" rating in a report on Wednesday, April 9th. Raymond James reissued a "strong-buy" rating and set a $360.00 target price (down from $415.00) on shares of The Cigna Group in a research report on Friday, January 31st. Finally, Oppenheimer lowered their target price on shares of The Cigna Group from $400.00 to $375.00 and set an "outperform" rating on the stock in a report on Friday, January 31st. Two research analysts have rated the stock with a hold rating, fifteen have assigned a buy rating and three have issued a strong buy rating to the stock. According to data from MarketBeat.com, The Cigna Group currently has a consensus rating of "Buy" and a consensus target price of $375.94.

The Cigna Group Stock Performance

NYSE CI opened at $334.49 on Monday. The company has a market capitalization of $91.54 billion, a P/E ratio of 27.38, a P/E/G ratio of 0.98 and a beta of 0.47. The company has a quick ratio of 0.72, a current ratio of 0.66 and a debt-to-equity ratio of 0.70. The Cigna Group has a 12-month low of $262.03 and a 12-month high of $370.83. The firm has a 50-day moving average price of $323.21 and a two-hundred day moving average price of $309.60.

The Cigna Group (NYSE:CI - Get Free Report) last released its quarterly earnings data on Friday, May 2nd. The health services provider reported $6.74 earnings per share (EPS) for the quarter, beating the consensus estimate of $6.35 by $0.39. The company had revenue of $65.45 billion during the quarter, compared to the consensus estimate of $60.39 billion. The Cigna Group had a return on equity of 18.61% and a net margin of 1.39%. The firm's revenue was up 14.4% compared to the same quarter last year. During the same quarter in the prior year, the firm posted $6.47 earnings per share. Analysts anticipate that The Cigna Group will post 29.77 earnings per share for the current year.

Insider Buying and Selling at The Cigna Group

In other news, Director Elder Granger sold 2,376 shares of the business's stock in a transaction dated Friday, March 14th. The shares were sold at an average price of $310.35, for a total value of $737,391.60. Following the sale, the director now directly owns 5,471 shares in the company, valued at $1,697,924.85. The trade was a 30.28 % decrease in their position. The transaction was disclosed in a filing with the SEC, which is available at the SEC website. Also, CEO David Cordani sold 26,527 shares of The Cigna Group stock in a transaction on Monday, March 3rd. The stock was sold at an average price of $308.12, for a total transaction of $8,173,499.24. Following the transaction, the chief executive officer now directly owns 127,767 shares of the company's stock, valued at $39,367,568.04. The trade was a 17.19 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last 90 days, insiders sold 43,751 shares of company stock worth $13,603,991. 0.70% of the stock is owned by insiders.

Institutional Inflows and Outflows

A number of institutional investors have recently added to or reduced their stakes in CI. Sterling Financial Group Inc. purchased a new position in The Cigna Group in the 4th quarter worth $4,367,000. Principal Financial Group Inc. boosted its holdings in The Cigna Group by 3.6% in the 3rd quarter. Principal Financial Group Inc. now owns 323,911 shares of the health services provider's stock valued at $112,216,000 after purchasing an additional 11,228 shares during the last quarter. Deroy & Devereaux Private Investment Counsel Inc. increased its stake in The Cigna Group by 1.1% during the fourth quarter. Deroy & Devereaux Private Investment Counsel Inc. now owns 75,837 shares of the health services provider's stock worth $20,942,000 after acquiring an additional 858 shares during the last quarter. Valley Wealth Managers Inc. increased its position in shares of The Cigna Group by 2.8% during the fourth quarter. Valley Wealth Managers Inc. now owns 56,933 shares of the health services provider's stock valued at $15,721,000 after acquiring an additional 1,548 shares during the last quarter. Finally, KBC Group NV raised its position in The Cigna Group by 1.5% in the fourth quarter. KBC Group NV now owns 550,638 shares of the health services provider's stock valued at $152,053,000 after purchasing an additional 8,077 shares during the period. Hedge funds and other institutional investors own 86.99% of the company's stock.

The Cigna Group Company Profile

The Cigna Group, together with its subsidiaries, provides insurance and related products and services in the United States. Its Evernorth Health Services segment provides a range of coordinated and point solution health services, including pharmacy benefits, home delivery pharmacy, specialty pharmacy, distribution, and care delivery and management solutions to health plans, employers, government organizations, and health care providers.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.